T2 Biosystems Inc (TTOO) Actualités

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

T2 Biosystems Announces Third Quarter 2024 Financial Results

LEXINGTON, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form PRE 14A - Other preliminary proxy statements

Form 8-K - Current report

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

T2 Biosystems to Report Third Quarter 2024 Financial Results and Business Updates on November 14, 2024

LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid...

Form 8-K - Current report

T2 Biosystems to Host Business Update Call on October 10, 2024

LEXINGTON, Mass., Oct. 08, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid...

T2 Biosystems, Inc. and Prxcision, Inc. Announce Co-Marketing Collaboration for Rapid Direct-From-Blood Diagnostics and AI-Powered Decision Support Platform

LEXINGTON, Mass. and SCHENECTADY, N.Y., Oct. 08, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO...

T2 Biosystems Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens

LEXINGTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) (the “Company”), a...

Form 8-K - Current report